Rare disease drug developer pays $6M after DoJ alleges 'kickback' scheme around lab tests

The payment will go to Medicare and Medicaid programs that the Justice Department alleges covered one of Ultragenyx's drugs; the company says its free-testing program saved those programs money.

Source: bizjournals.com Health Care:Biotechnology headlines - January 5, 2024 Category: Biotechnology Authors: Ron Leuty Source Type: news